Experimental immune cell combo targets Drug-Resistant lung cancer
NCT ID NCT07330050
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial is testing whether a new immune cell treatment called WAST cells, combined with the chemotherapy drug docetaxel, can shrink tumors or slow disease in people with advanced non-small cell lung cancer that has stopped responding to PD-1 inhibitors. The study plans to enroll 31 participants and will measure how many patients respond to the treatment, as well as how long they live without the cancer getting worse. The goal is to find a new option for patients who have run out of effective therapies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- WAST cells (a type of immune cell) and docetaxel (chemotherapy)
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced lung cancer that has stopped responding to standard immunotherapy.
- What could go wrong
- This is a small, early-phase trial with only 31 participants, so results may not apply to everyone. The treatment involves chemotherapy, which has known side effects like fatigue and infection risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC (NON-SMALL CELL LUNG CANCER) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin Medical University Cancer Institute and Hospital
RECRUITINGTianjin, Tianjin Municipality, 300060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immune drug outsmart Hard-to-Treat tumors?
- Can a pill plus immunotherapy and targeted radiation shrink lung tumors before surgery?
- Can a targeted drug combo boost chemoradiation in EGFR-Positive lung cancer?
- Cancer drug pralsetinib may change how the body processes other medications
- Blood test may let cancer patients take safe breaks from immunotherapy
- New pill takes on tough lung cancer mutation